Surface Engineering Promoted Insulin‐Sensitizing Activities of Sub‐Nanoscale Vanadate Clusters through Regulated Pharmacokinetics and Bioavailability
Abstract
The therapeutic application of vanadium compounds is plagued by their poor bioavailability and potential adverse effects. Herein, 1 nm polyoxovanadate (POV) clusters are functionalized with alkyl chains of various lengths and studied for the effect of surface engineering on their preclinical pharmacokinetics and typical insulin‐sensitizing activity. The concentrations of surface engineered POVs in plasma, urine, and feces are monitored after a single administration to rats. The POVs exhibit a two‐compartment profile of in vivo kinetics, and the surface engineering effect plays an important role in renal clearance of the POVs comparable to small molecules. POVs functionalized with long alkyl chains show much shorter elimination half timet1/2βand higher elimination fractions (50%) within 48 h than pristine POVs, suggesting favorable elimination kinetics to mitigate the possible side effects of vanadium. Meanwhile, long alkyl chain modification leads to a 76% increment of oral bioavailability in contrast to unmodified POVs. As suggested by glucose tolerance tests and sub‐chronic toxicity tests, the above two factors contribute to the enhanced therapeutic efficacy of POVs while mitigating their adverse effects. The surface engineering protocol provides a feasible approach to the optimization of the bioavailability and pharmacokinetic properties of POVs for promoted insulin‐sensitizing activities.Keywords
Funding Information
- Natural Science Foundation of Guangdong Province (2021A1515012024, 2021A1515010271)
This publication has 49 references indexed in Scilit:
- Facile synthesis of an organically-derivatized hexavanadate containing the remote amino group, TBA2[V6O13{(OCH2)3CNH2}2]CrystEngComm, 2016
- Vanadium compounds in medicineCoordination Chemistry Reviews, 2015
- Stimuli-responsive nanocarriers for drug deliveryNature Materials, 2013
- Titanium dioxide nanomaterials cause endothelial cell leakiness by disrupting the homophilic interaction of VE–cadherinNature Communications, 2013
- The Potentiality Of Vanadium In Medicinal ApplicationsFuture Medicinal Chemistry, 2012
- Vanadium treatment of type 2 diabetes: A view to the futureJournal of Inorganic Biochemistry, 2009
- Long-Term Acting and Orally Active Vanadyl-Methylpicolinate Complex with Hypoglycemic Activity in Streptozotocin-Induced Diabetic Rats.Journal of Clinical Biochemistry and Nutrition, 1997
- Pharmacokinetics of antiviral polyoxometalates in ratsAntimicrobial Agents and Chemotherapy, 1994
- Metronidazole in Anaerobic InfectionsDrugs, 1978
- Cefuroxime: Human PharmacokineticsAntimicrobial Agents and Chemotherapy, 1976